Used primarily as an intermediate in the synthesis of sulfa-based pharmaceutical compounds, particularly in the development of carbonic anhydrase inhibitors. These inhibitors are relevant in treating glaucoma, epilepsy, and certain types of edema. The compound's structure allows for selective binding to enzyme active sites, enhancing its pharmacological utility. It is also employed in research settings to design new sulfonamide derivatives with improved bioavailability and target specificity.